| __timestamp | Blueprint Medicines Corporation | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 4042025 |
| Thursday, January 1, 2015 | 14456000 | 5279557 |
| Friday, January 1, 2016 | 19218000 | 8073913 |
| Sunday, January 1, 2017 | 27986000 | 44864073 |
| Monday, January 1, 2018 | 47928000 | 53488904 |
| Tuesday, January 1, 2019 | 96388000 | 65896361 |
| Wednesday, January 1, 2020 | 157743000 | 69968267 |
| Friday, January 1, 2021 | 195293000 | 92047281 |
| Saturday, January 1, 2022 | 237374000 | 131819000 |
| Sunday, January 1, 2023 | 295141000 | 87501000 |
| Monday, January 1, 2024 | 359272000 |
Data in motion
In the competitive landscape of biotechnology, understanding the financial strategies of companies is crucial. Blueprint Medicines Corporation and Pharming Group N.V. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses over the past decade.
Since 2014, Blueprint Medicines has seen a staggering increase in SG&A expenses, growing by over 3,600% from 2014 to 2023. This reflects their aggressive expansion and investment in administrative capabilities, peaking at nearly $295 million in 2023.
In contrast, Pharming Group N.V. has maintained a more conservative growth trajectory, with SG&A expenses increasing by approximately 2,100% over the same period. Their expenses reached a high of $132 million in 2022, before slightly decreasing in 2023.
This comparison highlights the diverse strategies employed by biotech firms in managing operational costs.
Sanofi or Blueprint Medicines Corporation: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Pharming Group N.V.
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Pharming Group N.V.
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Blueprint Medicines Corporation
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Pharming Group N.V.
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Ionis Pharmaceuticals, Inc.
Blueprint Medicines Corporation vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Pharming Group N.V. and Madrigal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Pharming Group N.V. and Alpine Immune Sciences, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Pharming Group N.V. vs ADMA Biologics, Inc.
Pharming Group N.V. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?